Mutual of America Capital Management LLC lessened its holdings in shares of CareDx, Inc (NASDAQ:CDNA – Get Rating) by 4.2% during the 1st quarter, HoldingsChannel reports. The fund owned 71,321 shares of the company’s stock after selling 3,100 shares during the quarter. Mutual of America Capital Management LLC’s holdings in CareDx were worth $2,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also modified their holdings of the business. Montag A & Associates Inc. raised its position in shares of CareDx by 64.5% during the 4th quarter. Montag A & Associates Inc. now owns 579 shares of the company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Pinebridge Investments L.P. bought a new stake in shares of CareDx during the 4th quarter valued at $32,000. Hardy Reed LLC bought a new stake in shares of CareDx during the 1st quarter valued at $41,000. Sandy Cove Advisors LLC bought a new stake in shares of CareDx during the 4th quarter valued at $45,000. Finally, Dupont Capital Management Corp bought a new stake in shares of CareDx during the 4th quarter valued at $200,000.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. StockNews.com downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research report on Friday, April 8th. Stephens started coverage on shares of CareDx in a report on Monday, April 25th. They issued an “overweight” rating and a $50.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.80.
CareDx Price Performance
CareDx (NASDAQ:CDNA – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07). CareDx had a negative return on equity of 10.58% and a negative net margin of 16.09%. The firm had revenue of $79.42 million for the quarter, compared to analysts’ expectations of $78.63 million. As a group, sell-side analysts expect that CareDx, Inc will post -1.22 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Grace Colon sold 5,179 shares of CareDx stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $23.01, for a total transaction of $119,168.79. Following the completion of the transaction, the director now directly owns 2,522 shares of the company’s stock, valued at approximately $58,031.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.60% of the stock is owned by corporate insiders.
CareDx Company Profile
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Get a free copy of the StockNews.com research report on CareDx (CDNA)
- Can International Business Machines Recover After Its Sell-Off?
- Wingstop And Hershey Are Two Food Stocks Overcoming Inflation
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.